Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
SYS-CON.TV
Today's Top SOA Links


The Female Health Company Declares First Quarter Dividend and Extends Stock Repurchase Program

CHICAGO, Jan. 3, 2013 /PRNewswire/ -- The Female Health Company (NASDAQ-CM: FHCO) today announced that its Board of Directors has declared a quarterly cash dividend of $0.06 per share.  The dividend is payable February 6, 2013 to stockholders of record as of January 30, 2013.  In January 2010, the Company announced the initiation of a cash dividend program and has subsequently paid twelve consecutive quarterly dividends.

(Logo:  http://photos.prnewswire.com/prnh/20120712/MM39764LOGO)

The Board of Directors also extended the Company's stock repurchase program through December 31, 2013.  The program was previously due to expire at the end of calendar year 2012 and has a repurchase cap of 3 million shares of common stock.  The Company has repurchased approximately two million shares under the program, and approximately one million shares remain for potential repurchase.

"The Company's Board of Directors and management team believe that the payment of cash dividends allows shareholders to participate directly in the Company's success," stated O.B. Parrish, Chairman and Chief Executive Officer of The Female Health Company.  "The Company's profitability has generated cash from operations that exceeds the Company's capital spending requirements, and the Company remains debt-free.  We believe that utilizing some of this excess cash flow to pay cash dividends is in the best interests of our shareholders.  Extending the stock repurchase program provides another alternative for allocation of excess cash resources."

Any future quarterly dividends and the record date for any such dividends must be approved each quarter by the Company's Board of Directors and announced by the Company.  Payment of future dividends is at the discretion of the Board of Directors, which will base its decisions on operating cash flows, capital spending and other cash requirements, and other factors that may affect whether or not it believes the continued payment of dividends is in the best interests of the Company and its shareholders.  

About The Female Health Company

The Female Health Company, based in Chicago, Illinois, manufactures and markets the FC2 Female Condom® (FC2), which is available in the U.S. and approximately 138 other countries globally. The Company owns certain worldwide rights to the FC2 Female Condom®, including patents that have been issued by the U.S., the European Union, Canada, Australia, South Africa, Japan, The People's Republic of China, Spain, Mexico, Greece, Turkey and the African Regional Intellectual Property Organization (ARIPO), which includes Botswana, The Gambia, Ghana, Kenya, Lesotho, Malawi, Mozambique, Namibia, Sierra Leone, Somalia, Sudan, Swaziland, Uganda, United Republic of Tanzania, Zambia and Zimbabwe.  FC2 patent applications are pending in various countries.  The FC2 Female Condom® is the only available FDA-approved product controlled by a woman that offers dual protection against sexually transmitted diseases, including HIV/AIDS, and unintended pregnancy. The World Health Organization (WHO) has cleared FC2 for purchase by U.N. agencies. 

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:

The statements in this release which are not historical fact are "forward‑looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995.  Forward‑looking statements in this release relate to the continuation of cash dividends in future periods and the timing and amount of repurchases under the stock repurchase program.  These statements are based upon the Company's current plans and strategies, and reflect the Company's current assessment of the risks and uncertainties related to its business, and are made as of the date of this release.  The Company assumes no obligation to update any forward‑looking statements contained in this release as a result of new information or future events, developments or circumstances.  Such forward‑looking statements are inherently subject to known and unknown risks and uncertainties.  The Company's actual results and future developments could differ materially from the results or developments expressed in, or implied by, these forward‑looking statements.  Factors that may cause actual results to differ materially from those contemplated by such forward‑looking statements include, but are not limited to, the following:  product demand and market acceptance; competition in the Company's markets and the risk of new competitors and new competitive product introductions; the Company's reliance on its international partners in the consumer sector and on the level of spending on the female condom by country governments, global donors and other public health organizations in the global public sector; the economic and business environment and the impact of government pressures; risks involved in doing business on an international level, including currency risks, regulatory requirements, political risks, export restrictions and other trade barriers; the Company's production capacity, efficiency and supply constraints; and other risks detailed in the Company's press releases, shareholder communications and Securities and Exchange Commission filings, including the Company's Form 10‑K for the fiscal year ended September 30, 2012.  Actual events affecting the Company and the impact of such events on the Company's operations may vary from those currently anticipated.

For more information about the Female Health Company visit the Company's website at http://www.femalehealth.com  and http://www.femalecondom.org . If you would like to be added to the Company's e-mail alert list, please send an e-mail to FHCInvestor@femalehealthcompany.com

SOURCE The Female Health Company

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Web 2.0 Latest News
I've been writing recently about the dimensions of Big Data in the IoT: urgency, importance, frequency, consequences, remedy, cost. You can find my stories on IoT Journal or at my personal website. The big item missing from this list is, of course, size. How big are individual messa...
We are formally announcing the IoT Project Framework at @ThingsExpo Nov 4-6 in Santa Clara, CA. it will feature four overriding goals for the IoT in the year 2040: 1. To reduce poverty & disease 2. To eliminate violence as a way of settling disputes 3. To spur beneficial economic ...
With Octoblu emerging from stealth mode, it seemed like a good idea to talk to a couple of key people there. We were able to do just that with company co-founders Geir Ramleth and Chris Matthieu. Geir Ramleth serves as CEO. He was named to CIO Magazine's Hall of Fame in 2008, and ser...
I had a fun conversation with Mark Van Rijmenam (@VanRijmenam) a couple of weeks ago about cloud computing, Big Data, and the IoT. Mark runs BigData-Startups.com in Den Haag, Netherlands. We were mutually amused that he had chosen the name Think Bigger for his new book just as I had ch...
“Vote early and vote often.” Back in the 1920s and ’30s, when neither election technology nor oversight were as effective as they are today, and the likes of Al Capone were at work gaming the system, this phrase wasn’t a joke. It was a best practice. If you want guaranteed results, wh...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021




SYS-CON Featured Whitepapers
ADS BY GOOGLE